These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33825830)

  • 21. Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer.
    Kang BW; Jeon HS; Chae YS; Lee SJ; Park JS; Choi GS; Kim JG
    Anticancer Res; 2016 Jul; 36(7):3353-61. PubMed ID: 27354594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2.
    Fan C; Lin Y; Mao Y; Huang Z; Liu AY; Ma H; Yu D; Maitikabili A; Xiao H; Zhang C; Liu F; Luo Q; Ouyang G
    Oncotarget; 2016 Apr; 7(16):21825-39. PubMed ID: 26968810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single nucleotide polymorphisms within MicroRNAs, MicroRNA targets, and MicroRNA biogenesis genes and their impact on colorectal cancer survival.
    Mullany LE; Herrick JS; Wolff RK; Slattery ML
    Genes Chromosomes Cancer; 2017 Apr; 56(4):285-295. PubMed ID: 27859935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rs17084733 variant in the
    Ravegnini G; Serrano C; Simeon V; Sammarini G; Nannini M; Roversi E; Urbini M; Ferrè F; Ricci R; Tarantino G; Pantaleo MA; Hrelia P; Angelini S
    Epigenetics; 2019 Jun; 14(6):545-557. PubMed ID: 30983504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status.
    Myte R; Gylling B; Häggström J; Schneede J; Löfgren-Burström A; Huyghe JR; Hallmans G; Meyer K; Johansson I; Ueland PM; Palmqvist R; Van Guelpen B
    PLoS One; 2018; 13(4):e0196233. PubMed ID: 29694444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
    Schou JV; Rossi S; Jensen BV; Nielsen DL; Pfeiffer P; Høgdall E; Yilmaz M; Tejpar S; Delorenzi M; Kruhøffer M; Johansen JS
    PLoS One; 2014; 9(6):e99886. PubMed ID: 24940606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
    Huang X; Yang Y; Guo Y; Cao ZL; Cui ZW; Hu TC; Gao LB
    Genet Mol Res; 2015 Dec; 14(4):16913-20. PubMed ID: 26681038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
    Gutiérrez-Malacatt H; Ayala-Sanchez M; Aquino-Ortega X; Dominguez-Rodriguez J; Martinez-Tovar A; Olarte-Carrillo I; Martinez-Hernandez A; C CC; Orozco L; Cordova EJ
    Asian Pac J Cancer Prev; 2016; 17(4):2265-70. PubMed ID: 27221928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
    Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB
    Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miRNAs-Based Molecular Signature for
    Milanesi E; Dobre M; Bucuroiu AI; Herlea V; Manuc TE; Salvi A; De Petro G; Manuc M; Becheanu G
    J Immunol Res; 2020; 2020():4927120. PubMed ID: 32676506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
    Chu PC; Lin PC; Wu HY; Lin KT; Wu C; Bekaii-Saab T; Lin YJ; Lee CT; Lee JC; Chen CS
    Oncogene; 2018 Jun; 37(25):3440-3455. PubMed ID: 29559746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA Expression in
    Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
    Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer.
    Kim JG; Chae YS; Lee SJ; Kang BW; Park JY; Lee EJ; Jeon HS; Park JS; Choi GS
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):35-41. PubMed ID: 25079514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
    Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single nuclear polymorphism in let-7g binding site affects the doubling time of thyroid nodule by regulating KRAS-induced cell proliferation.
    Liu A; Zhang W; Zhao T; Xiao M; Mei Q; Zhu H
    J Cell Physiol; 2019 Dec; 234(12):23437-23447. PubMed ID: 31152438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.